

90.00 mm

For the use only of a Registered Veterinary Practitioner or a Hospital or a Laboratory or a Farm.

Moxidectin and Praziquantel Oral Gel

MoxiRace™ Gold

2 in 1 Wormer

2 in 1 Combination Wormer for Horses & Ponies.

COMPOSITION:

Each gram contains :
 Moxidectin BP20 mg
 Praziquantel USP125 mg
 Excipientsq.s.

INDICATIONS:

MoxiRace Gold is indicated for the treatment of mixed cestodes and nematodes or arthropods infections in horses, caused by moxidectin and praziquantel sensitive strains of:

Large strongyles:

• *Strongylus vulgaris* (adult stages) • *Strongylus edentatus* (adult stages)
 • *Triodontophorus brevicauda* (adults) • *Triodontophorus serratus* (adults) • *Triodontophorus tenuicollis* (adults)

Small strongyles (adult and intraluminal larval stages):

• *Cyathostomum* spp • *Cylicocyclus* spp • *Cylicostephanus* spp • *Cylicodontophorus* spp • *Gyaloccephalus* spp

Ascarids:

• *Parascaris equorum* (adults)

Other species:

• *Oxyuris equi* (adult stages) • *Habronema muscae* (adults) • *Gasterophilus intestinalis* (L2, L3) • *Gasterophilus nasalis* (L2, L3)
 • *Strongyloides westeri* (adults) • *Trichostrongylus axei* (adult stages)

Tapeworm (adults):

• *Anoplocephala perfoliata* • *Anoplocephala magna* • *Paranoplocephala mammillana*

The egg reappearance period of small strongyles is 90 days.

The product is effective against (developing) intramucosal L4 stages of small strongyles.

At 8 weeks after treatment, early (hypobiotic) EL3 stages of small strongyles are eliminated.

DOSAGE AND ADMINISTRATION:

A single oral dose of 400 µg moxidectin/kg bodyweight and 2.5 mg praziquantel/kg bodyweight using the calibrated syringe of one gradation per 25 kg body weight.

Do not underdose

For oral use only.

A single syringe treats a 700 kg horse.

In the case of cestode treatment the dose of praziquantel in the product has been selected to the top end of the dosing range.

DIRECTIONS FOR USE:

• It is intended for use only with the dispensing syringe designed for this product.

- Determine the Accurate weight of the horse.
- Set the correct dose rate by turning the plunger lock.
- Remove the cap from the end of the syringe.

- Horse's Mouth must be free of food.

• Insert the syringe nozzle into the side of the horse's mouth, in the gap between the front and back teeth. Advance the syringe as far as possible into the mouth, and deposit the paste onto the back of the tongue by pressing the plunger completely to give the measured dose.

- Immediately after administration, raise the horse's head & hold for a few seconds to ensure the full dose is swallowed.

- Replace the syringe cap.

• Repeat doses should be given every 6-8 weeks in young and all susceptible horses. When using good control measures to reduce reinestation, mature horses only require treatment 3-4 times a year.

Administration:**Oral****TARGET SPECIES:**

Horses & Ponies.

PHARMACODYNAMIC PROPERTIES:

Pharmacotherapeutic group: antiparasitic product, endectocycle

ATCVet code: QP54AB52, moxidectin combination

120.00 mm

Front

PHARMACODYNAMICS:

Moxidectin is a parasiticide active against a wide range of internal and external parasites and is a second generation macrocyclic lactone of the milbemycin family. Moxidectin interacts with GABA receptors and chloride channels. The net effect is to open the chloride channels on the postsynaptic junction to allow the inflow of chloride ions and induce an irreversible resting state. This results in flaccid paralysis and eventual death of parasites exposed to the drug.

Praziquantel is a parasiticide widely used in many species as an anthelmintic. Praziquantel is quickly absorbed via the tegument of the parasite and distributed. *In vitro* and *in vivo* important lesions of the tegument of the parasite are seen that provoke contraction and paralysis of the parasite.

Praziquantel modifies the permeability of the parasitic membrane to calcium ions, which disrupts the metabolism of the parasite.

Moxidectin is effective against benzimidazole resistant strains of cyathostomes.

PHARMACOKINETICS:

Moxidectin is absorbed orally and maximum blood concentration is achieved approximately 6 to 8 hours after administration. The drug is distributed throughout the body tissues but due to its lipophilicity it is selectively concentrated in the fat. The elimination half-life is 11days. Moxidectin undergoes partial biotransformation by hydroxylation in the body and the only significant route of excretion is the faeces.

Praziquantel is quickly and almost totally absorbed in the body, rapidly distributed to all organs, half life elimination is less than 1 hour in horses.

Praziquantel is rapidly metabolised in the liver. Its principal metabolite is a related 4-hydroxycyclohexyl component.

WARNING & PRECAUTION:**Special warnings for each target species:**

During treatment with the product animals must have free and easy access to drinking water.

Too frequent and repeated use of anthelmintics from the same class, over an extended period of time should be avoided as it increases the risk of development of resistance and could ultimately result in ineffective therapy.

Special Precautions For Use:

Special precautions for use in animals:

- Do not use the same syringe in more than one animal.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

- Wear gloves during application.
- Wash the hands thoroughly after use.
- Do not eat, drink or smoke while handling this product.
- Assess bodyweight as accurately as possible before calculating the dosage.
- In case of accidental eye contact, rinse immediately with plenty of water.
- In case of accidental ingestion or eye irritation, seek medical advice and show the package leaflet or label to the physician.

CONTRAINDICATIONS:

Hypersensitivity to any of the Ingredients.

Do not administer to animals other than those for which it is indicated.

Do not administer to young foals less than 6.5 months old.

ADVERSE EFFECTS:

Mouth pain, flaccid lower lip and swelling of the muzzle, hyper salivation and anorexia could be observed on rare occasions in young animals. These adverse effects are usually transient and disappear spontaneously in most cases.

PREGNANCY AND LACTATION:

The veterinary medicinal product has been shown to be safe for use in pregnant and lactating mares.

The administration of the product does not adversely affect the fertility of the mares.

OVERDOSAGE:

Transient adverse reactions may occur at 3 times the recommended dose in adults.

The symptoms are depression, inappetence, ataxia, flaccid lower lip in the 8 to 24 hours following treatment. Symptomatic treatment is not generally necessary and recovery is generally complete within 24 to 72 hours. There is no specific antidote.

WITHDRAWAL PERIOD:

Meat & Offal: 64 days after the latest treatment

Milk: Not allowed for use in Horses producing milk for human consumption.

STORAGE:

Store below 25°C.

Discard after 6 months from the date of the first use.

PRESENTATION:

14 x Syringe packed in a Primary Carton along with the Pack Insert.

KEEP OUT OF REACH OF CHILDREN & PETS, AWAY FROM FOOD.

Carefully read the accompanying instructions before use.

MANUFACTURED & MARKETED BY:

Veko®

VEKO CARE PVT. LTD.

Plot No. E - 48 & 49, MIDC ,

Ranjangaon, District - Pune , Maharashtra , INDIA. Pin Code : 412220.

Customer care : care@vekocare.com **TM** : Trademark of Veko Care.

FOR VETERINARY USE.
 NOT FOR HUMAN USE.
 FOR ANIMAL TREATMENT ONLY.

VPP1E283



Back